Acute Lung Injury Market Share, Size, Symptoms, Treatment, Causes, Analysis, Overview and Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Acute Lung Injury - Pipeline Review, H1 2016', provides an overview of the Acute Lung Injury pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acute Lung Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Lung Injury and features dormant and discontinued projects.

Browse Complete Summary, Click Here @ http://www.radiantinsights.com/research/acute-lung-injury-pipeline-review-h1-2016

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Buy a Sample Copy of This Report @ http://www.radiantinsights.com/research/acute-lung-injury-pipeline-review-h1-2016/request-sample

C-X-C Chemokine Receptor Type 1 (CDw128a) Market Symptoms, Treatment, Overview and Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin-8 Receptor A or IL-8 Receptor Type 1 or CD181 or CXCR1) - Pipeline Review, H1 2016', provides in depth analysis on C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin-8 Receptor A or IL-8 Receptor Type 1 or CD181 or CXCR1) targeted pipeline therapeutics.

The report provides comprehensive information on the C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin-8 Receptor A or IL-8 Receptor Type 1 or CD181 or CXCR1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin-8 Receptor A or IL-8 Receptor Type 1 or CD181 or CXCR1) targeted therapeutics development and features dormant and discontinued projects.

Access Full Report with TOC @ http://www.radiantinsights.com/research/c-x-c-chemokine-receptor-type-1

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Buy a Sample Copy of This Report @ http://www.radiantinsights.com/research/c-x-c-chemokine-receptor-type-1/request-sample

Atypical Chemokine Receptor 3 (G-Protein Coupled Receptor RDC1 Homolog) Market Share, Symptoms, Treatment, Causes, Analysis and Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Atypical Chemokine Receptor 3 (Chemokine Orphan Receptor 1 or G-Protein Coupled Receptor 159 or G-Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7) - Pipeline Review, H1 2016', provides in depth analysis on Atypical Chemokine Receptor 3 (Chemokine Orphan Receptor 1 or G-Protein Coupled Receptor 159 or G-Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7) targeted pipeline therapeutics.

The report provides comprehensive information on the Atypical Chemokine Receptor 3 (Chemokine Orphan Receptor 1 or G-Protein Coupled Receptor 159 or G-Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Atypical Chemokine Receptor 3 (Chemokine Orphan Receptor 1 or G-Protein Coupled Receptor 159 or G-Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7) targeted therapeutics development and features dormant and discontinued projects.

Access Full Report with TOC @ http://www.radiantinsights.com/research/atypical-chemokine-receptor-3

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data..

Buy a Sample Copy of This Report @ http://www.radiantinsights.com/research/atypical-chemokine-receptor-3/request-sample

About Us:

Radiant Insights Inc. is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

Contact Details:

Michelle Thoras

Corporate Sales Specialist, USA

Radiant Insights, Inc

28 2nd Street,

Suite 3036 San Francisco,

CA 94105 United States

Phone: 1-415-349-0054

Toll Free: 1-888-202-9519

Website: http://www.radiantinsights.com/

Email: sales@radiantinsights.com

Visit our Blog: http://chemicalsandmaterialsri.blogspot.com

AVEO Pharmaceuticals, Inc Market Share, Size, Symptoms, Treatment, Overview and Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'AVEO Pharmaceuticals, Inc. - Product Pipeline Review - 2016', provides an overview of the AVEO Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by AVEO Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

To Get Full Report Click Here @ http://www.radiantinsights.com/research/aveo-pharmaceuticals-inc-product-pipeline-review-2016

Progressive Multifocal Leukoencephalopathy Market Share, Size, Symptoms, Treatment, Analysis, Overview and Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Progressive Multifocal Leukoencephalopathy - Pipeline Review, H1 2016', provides an overview of the Progressive Multifocal Leukoencephalopathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Progressive Multifocal Leukoencephalopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Progressive Multifocal Leukoencephalopathy and features dormant and discontinued projects.

Browse Full Report with TOC @ http://www.radiantinsights.com/research/progressive-multifocal-leukoencephalopathy-pipeline-review-h1-2016

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Progressive Multifocal Leukoencephalopathy

- The report reviews pipeline therapeutics for Progressive Multifocal Leukoencephalopathy by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Progressive Multifocal Leukoencephalopathy therapeutics and enlists all their major and minor projects

- The report assesses Progressive Multifocal Leukoencephalopathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Progressive Multifocal Leukoencephalopathy

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Progressive Multifocal Leukoencephalopathy

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Progressive Multifocal Leukoencephalopathy pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Buy a Sample Copy of This Report @ http://www.radiantinsights.com/research/progressive-multifocal-leukoencephalopathy-pipeline-review-h1-2016/request-sample

Patient Engagement Solutions Market is Expected to Reach USD 39.3 Billion by 2024: Radiant Insights

The global patient engagement solutions market is expected to reach USD 39.3 billion by 2024, according to a new report by Grand View Research, Inc. The supportive government initiatives and the rising usage and awareness of mobile healthcare services are expected to impel the market growth.

The rising prevalence of chronic conditions is the preliminary factor that is expected to advance the market growth. The mortality rate of diabetic patients was over 1.0 million in 2012, as stated by the WHO. This hike in the death rate of diabetic patients reflects the lack of knowledge about the causes, symptoms, and the preventive measures of the disease. The present patient engagement systems aid in furnishing patients with educative information; thus, empowering them to make better healthcare decisions.

Browse Full Report with TOC @ http://www.radiantinsights.com/research/patient-engagement-solutions-market

The patient engagement solutions cater to the hospitals in providing financial solutions for effective utilization of the allocated healthcare budget. Furthermore, the market players are actively volunteering in obtaining patient feedback regarding the existent solutions to develop better patient engagement plat forms with enhanced quality.

Moreover, the favorable government initiatives and the funding efforts undertaken to promote the incorporation of patient engagement solutions in the healthcare sector help in boosting the market growth. For instance, in the U.S., under the Health Information Technology for Economic and Clinical Health (HITECH) act, the government spends around USD 20 billion annually on hospitals for the installation of Electronic Health Records (EHRs), which is expected to help in improving the workflow and the quality of treatment delivery.

Further key findings from the study suggest:

The web-based delivery segment is expected to be the largest delivery mode growing at a lucrative CAGR over the forecast period.

North America is expected to dominate over the forecast period with a revenue share of over 40.0% in 2024. Favourable government initiatives, such as the Affordable Care Act (ACA) initiated by President Obama and the Health Information Technology for Economic and Clinical Health (HITECH) act, are anticipated to drive the market growth.

Asia Pacific is anticipated to emerge as the fastest growing region with a CAGR of over 20.0% over the forecast period. The increasing investments in the healthcare sector, rising awareness with regard to the varying types of patient engagement portals, and the escalating geriatric population base are estimated to catapult the demand.

Some key players of the market include Allscripts Healthcare Solutions, Inc., Cerner Corporation, Phytel, Inc., Athenahealth, Inc., McKesson Corporation, and MEDecision, Inc.

In order to curtail the competition, the key industry players are actively involved in the development of new solutions that facilitate the workflow of the existing platforms. For instance, Allscripts Healthcare Solutions, Inc. provides revenue cycle management solutions, which help in maintaining the financial health of the medical systems.

Buy a Sample Copy of This Report @ http://www.radiantinsights.com/research/patient-engagement-solutions-market/request-sample

Dermatomycoses Market Share, Size, Symptoms, Treatment, Causes, Analysis, Overview and Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Dermatomycoses - Pipeline Review, H1 2016', provides an overview of the Dermatomycoses pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Dermatomycoses, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dermatomycoses and features dormant and discontinued projects.

Click Here For Complete Report @ http://www.radiantinsights.com/research/dermatomycoses-pipeline-review-h1-2016

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Buy a Sample Copy of This Report @ http://www.radiantinsights.com/research/dermatomycoses-pipeline-review-h1-2016/request-sample